An interventional study of omega-3 and Standard in Sarcopenia, sponsored by Maimónides Biomedical Research Institute of Córdoba. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-06.
Sponsored by Maimónides Biomedical Research Institute of Córdoba · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Sarcopenia with a site in Spain — 33 open to participants now, 40 under way, none of them phase 3. Sarcopenia · Spain.
Among the 99 studies in Sarcopenia with a site in Spain, this one is the 60th largest by planned enrollment of the 77 interventional ones that give a count, is one of 6 that started in 2023, is one of 70 with no phase, reaches primary completion later than 20 of the 39 other live ones, and was the 54th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →33 of the 99 studies in Sarcopenia with a site in Spain are open now. Recruiting first, the newest first:
University of Valencia · Sites in Spain
Ages 18–99
Universidad de Granada · Sites in Spain
Ages 65+
University of Salamanca · Sites in Spain
Ages 18+
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Sites in Spain
Ages 80+
Sara Casanova Prieto · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 6 started in 2023.
This study's planned enrollment of 40 is below the median of 60 across 860 interventional studies indexed under Sarcopenia.
Median enrollment 72 across the 77 interventional studies, 156 across the 22 observational. Of the 48 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 99 have an industry lead sponsor. The 10 most frequent:
Maimónides Biomedical Research Institute of Córdoba is the lead sponsor of 79 studies on the registry; 19 are open to participants now.
Maimónides Biomedical Research Institute of Córdoba has 4 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
15 of the studies in Sarcopenia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387770University of SalamancaMuscle Deterioration in Hospitalized Cancer Patient | 2026-11-30 |
| NCT07275996Universidad de BurgosNeuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty | 2026-12-30 |
| NCT06634316Maimónides Biomedical Research Institute of CórdobaSarcopenia in Patients With Heart Failure | 2026-12-31 |
| NCT07447375University of SalamancaExercise During Hemodialysis: Impact on Sarcopenia and Sleep Quality | 2026-12-31 |
| NCT06015971Maimónides Biomedical Research Institute of CórdobaOmega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 99 studies in Sarcopenia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sarcopenia is a frequent complication in patients with cancer and chronic diseases, it is characterized by decreased muscle strength and fatigue due to reduced skeletal muscle mass, which is accompanied by atrophy and decreased quality of muscle tissue. In all cases, it negatively impacts treatment tolerance, clinical outcomes and survival, in consequence, quality of life of these patients decreases while morbidity, mortality and costs increase. In this context, appropriate nutritional screening and early nutrition support are extremely recommended, to this aim, in some cases, oral nutritional supplements (ONS) are necessary; ONS could have a standard formula or be enriched with specific nutrients (arginine, glutamine, branched chain amino acids, n-3 fatty acids, and nucleotides), which can modulate the activity of the immune system and provide an additional benefit beyond the nutritional support, this intervention type is called immunonutrition. Despite these possible benefits, their utility has been proven in few clinical scenarios, for example in with patients with upper gastrointestinal cancer undergoing surgical resection; based on this, current guidelines recommend that patients should receive oral/enteral nutritional support with an specific formula enriched in immunonutrients (with arginine, n-3 fatty acids or nucleotides) , but there is a lack of evidence for supporting its use in other clinical conditions including patients with cancer that receive systemic treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Supplement: Standard
Dietary Supplement: omega-3
Take 2 omega-3 enriched oral supplements per day plus physical activity and Mediterranean Diet
Take 2 hypercaloric hyperproteic oral supplements per day plus physical activity and Mediterranean Diet
Muscle mass
Muscle mass change (in Kg)
Time frame: 12 weeks
Functionality
Changes in functionality measured with the Up and Go Test
Time frame: 12 weeks
Albumin
Changes in serum albumin levels (g/dl)
Time frame: 12 weeks
C-RP
Changes in serum C-RP(g/dl)
Time frame: 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.
Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 41 months is above that.
Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omega-3 fatty acid
Maimónides Biomedical Research Institute of Córdoba